Abstract:Anti-TNF antibody has been an effective therapeutic strategy for the diseases related to aberrant production of TNF-alpha, such as rheumatoid arthritis (RA) and Crohn's disease. The limitations of large molecule inhibitors in the therapy of these diseases prompted the search for other potent novel TNF-alpha antagonists. Antagonistic peptides, derived directly or designed rationally from complementarity-determining regions (CDRs) of neutralizing antibodies against TNF-alpha, have been demonstrated for their ability of inhibiting TNF-alpha. However, their activity is very low. In this study, to increase the affinity and bioactivity, human antibody variable region was used as scaffold to display antagonistic peptides, which were designed on the interaction between TNF-alpha and its neutralizing monoclonal antibody (mAb Z12). Based on the previously designed domain antibody (framework V(H)5), framework V(kappa)1 was used as light chain scaffold. On the basis of computer-guided molecular design method, a novel human scFv fragment (named as TSA1) was designed. Theoretical analysis showed that TSA1 could bind to TNF-alpha with more hydrogen bonds and lower binding free energy than the designed domain antibody. The biological experiments demonstrated that TSA1 could directly bind with TNF-alpha, competitively inhibit the binding of mAb Z12 to TNF-alpha and block the binding of TNF-alpha to TNFR I and TNFR II. TSA1 could also inhibit TNF-induced cytotoxicity on L929 cells and TNF-mediated NF-kappaB activation on HEK-293T cells. The bioactivity of TSA1 was significantly increased over the domain antibody. This study indicated that the framework of antibody variable region could serve as an ideal scaffold for displaying the peptides and provides a novel strategy to design TNF-alpha inhibitors with the ability to block the deleterious biological effects of TNF-alpha.

A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody As Scaffolds to Display Antagonistic Peptides

A Novel Human Scfv Fragment Against Tnf-Alpha from De Novo Design Method

Novel human single chain antibody design based on the functional epitope of TNF

A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody

Overexpression, Effective Renaturation, and Bioactivity of Novel Single-Chain Antibodies Against TNF-α

Overexpression, Effective Renaturation, And Bioactivity Of Novel Single-Chain Antibodies Against Tnf-Alpha

De Novo Design TNF-α Antagonistic Peptide Based on the Complex Structure of TNF-α with Its Neutralizing Monoclonal Antibody Z12

A novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides

Covalently dimerized Camelidae antihuman TNFa single-domain antibodies expressed in yeast Pichia pastoris show superior neutralizing activity

Retraction Note To: Structure-based Development and Optimization of Therapy Antibody Drugs Against TNFα

The Protective Antibodies Induced by a Novel Epitope of Human TNF-α Could Suppress the Development of Collagen-Induced Arthritis

Targeting TNF-α with a tetravalent mini-antibody TNF-TeAb

Humanization of an Anti-Human Tnf-Alpha Antibody by Variable Region Resurfacing with the Aid of Molecular Modeling

Designing and constructing a phage display synthesized single domain antibodies library based on camel VHHs frame for screening and identifying humanized TNF-α-specific nanobody

Characterization of a novel anti-human TNF-α murine monoclonal antibody with high binding affinity and neutralizing activity

Preparation and Characterization of a Fully Human Monoclonal Antibody Specific for Human Tumor Necrosis Factor Alpha

Preparation and identification of transmembrane TNF-α(TM-TNF-α)specific monoclonal antibody

A novel single domain bispecific antibody targeting VEGF and TNF-α ameliorates rheumatoid arthritis

Novel peptide inhibitor of human tumor necrosis factor-α has antiarthritic activity

Rational Design of Potent Mimic Peptide Derived from Monoclonal Antibody: Antibody Mimic Design.

A Tumor Necrosis Factor (TNF) Receptor-Igg Heavy Chain Chimeric Protein As a Bivalent Antagonist of TNF Activity.